Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Zhang, Shijie ^a   Wang, Lei ^a   Liu, Hongchun ^a   Zhao, Guoqiang ^b   Ming, Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Myricetin; Pulmonary carcinoma; Radiosensitizer; Radiotherapy

Indexed keywords

FLAVONOID; MYRICETIN; RADIOSENSITIZING AGENT;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; MOUSE; NUDE MOUSE; RADIATION DOSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899138736     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-68     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Nygren P, Glimelius B. The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy-Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001, 40:155-165. 10.1080/02841860151116187, 11441928.
3. Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat 2009, 19:643-662. 10.1517/13543770902824172, 19441939.
4. Takehito S. Factors determining radioresistance of tumors. Kokubyo Gakkai Zasshi 2003, 70:162-168. 10.5357/koubyou.70.162, 14577338.
5. Impicciatore G, Sancilio S, Miscia S, Di Pietro R. Nutlins and ionizing radiation in cancer therapy. Curr Pharm Des 2010, 16:1427-1442. 10.2174/138161210791033932, 20166982.
6. Raleigh DR, Haas-Kogan DA. Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol 2013, 9:219-233. 10.2217/fon.12.185, 3635474, 23414472.
7. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?. Radiother Oncol 2004, 72:305-310. 10.1016/j.radonc.2004.07.002, 15450729.
8. Kastan MB. Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta 1999, 1424:37-42.
9. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999, 59:4375-4382.
10. Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, Valerie K. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 2012, 11:1167-1173. 10.4161/cc.11.6.19576, 3335919, 22370485.
11. De Wever O, Sobczak-Thépot J, Vercoutter-Edouart AS, Michalski JC, Ouelaa-Benslama R, Stupack DG, Bracke M, Wang JY, Gespach C, Emami S. Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol 2011, 39:393-400.
12. Kabakov AE, Kudryavtsev VA, Gabai VL. Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 2010, 88:241-247. 10.1007/s00109-009-0562-0, 19946660.
13. Illum H. Current status of radiosensitizing agents for the management of rectal cancer. Crit Rev Oncog 2012, 17:345-359. 10.1615/CritRevOncog.v17.i4.40, 23176042.
14. Ong KC, Khoo HE. Biological effects of myricetin. Gen Pharmacol 1997, 29:121-126. 10.1016/S0306-3623(96)00421-1, 9251891.
15. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34. 10.1146/annurev.nutr.22.111401.144957, 12055336.
16. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev 2012, 31:323-351. 10.1007/s10555-012-9347-y, 22314287.
17. Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012, 64:599-606. 10.1080/01635581.2012.665564, 22482362.
18. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, Bode AM, Bowden GT, Lee HJ, Dong Z. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 2008, 68:6021-6029. 10.1158/0008-5472.CAN-08-0899, 18632659.
19. Fahlman BM, Krol ES. UVA and UVB radiation-induced oxidation products of quercetin. J Photochem Photobiol B 2009, 97:123-131. 10.1016/j.jphotobiol.2009.08.009, 19782575.
20. Fahlman BM, Krol ES. Inhibition of UVA and UVB radiation-induced lipid oxidation by quercetin. J Agric Food Chem 2009, 57:5301-5305. 10.1021/jf900344d, 19530712.
21. Benković V, Kopjar N, Horvat Knezevic A, Dikić D, Basić I, Ramić S, Viculin T, Knezević F, Orolić N. Evaluation of radioprotective effects of propolis and quercetin on human white blood cells in vitro. Biol Pharm Bull 2008, 31:1778-1785. 10.1248/bpb.31.1778, 18758076.
22. Lin C, Yu Y, Zhao HG, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol 2012, 104:395-400. 10.1016/j.radonc.2011.10.023, 22119371.
23. Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M. IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 2012, 7:165. 10.1186/1746-1596-7-165, 3533585, 23190601.
24. Baumann M, Stamatis G, Thomas M. Therapy of localized non-small cell lung cancer (take home messages). Lung Cancer 2001, 33:S47-S49.
25. Gressen EL, Curran WJ. Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep 2000, 2:71-75. 10.1007/s11912-000-0013-0, 11122827.
26. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 1999, 47:2274-2279. 10.1021/jf9811065, 10794622.
27. Khamidullina EA, Gromova AS, Lutsky VI, Owen NL. Natural products from medicinal plants: non-alkaloidal natural constituents of the Thalictrum species. Nat Prod Rep 2006, 23:117-129. 10.1039/b504014k, 16453035.
28. Chang RL, Huang MT, Wood AW, Wong CQ, Newmark HL, Yagi H, Sayer JM, Jerina DM, Conney AH. Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10- tetrahydrobenzo[a] pyrene on mouse skin and in the newborn mouse. Carcinogenesis 1985, 6:1127-1133. 10.1093/carcin/6.8.1127, 3926336.
29. Das M, Khan WA, Asokan P, Bickers DR, Mukhtar H. Inhibition of polycyclic aromatic hydrocarbon-DNA adduct formation in epidermis and lungs of SENCAR mice by naturally occurring plant phenols. Cancer Res 1987, 47:767-773.
30. Pustisek N, Situm M. UV-radiation, apoptosis and skin. Coll Antropol 2011, Suppl 2:339-341.
31. Lee CL, Blum JM, Kirsch DG. Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl Cancer Res 2013, 2:412-421. 3898670, 24466508.
32. Hensley P, Mishra M, Kyprianou N. Targeting caspases in cancer therapeutics. Biol Chem 2013, 394:831-843.
33. Grosse J, Grimm D, Westphal K, Ulbrich C, Moosbauer J, Pohl F, Koelbl O, Infanger M, Eilles C, Schoenberger J. Radiolabeled annexin V for imaging apoptosis in radiated human follicular thyroid carcinomas-is an individualized protocol necessary?. Nucl Med Biol 2009, 36:89-98. 10.1016/j.nucmedbio.2008.10.004, 19181273.
34. Shinomiya N. New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. J Cell Mol Med 2001, 5:240-253. 10.1111/j.1582-4934.2001.tb00158.x, 12067483.
35. Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm 2011, 26:203-238. 10.1089/cbr.2010.0871, 21539452.